Galmed pharmaceuticals announces receipt of nasdaq minimum bid price notification

Tel aviv, israel , june 17, 2022 /prnewswire/ -- galmed pharmaceuticals ltd. (nasdaq: glmd) ("galmed" or the "company"), a clinical-stage biopharmaceutical company for liver, metabolic, fibrosis and inflammatory diseases today announced that the company received a letter from the nasdaq listing qualifications (the "letter"), indicating that the company is not in compliance with the minimum bid price requirement for continued listing set forth in listing rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share.
GLMD Ratings Summary
GLMD Quant Ranking